Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02870829
Other study ID # NHG DSRB Ref: 2015/01000
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 2016
Est. completion date February 2022

Study information

Verified date January 2023
Source National University Health System, Singapore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed study will seek to evaluate the prevalence and the progression of vascular calcification in a cohort of maintenance hemodialysis patients in Asian population. It will also evaluate the efficacy of vitamin K 2 supplementation in reducing the progression of vascular calcification in this group of patients. This will be a single-center randomized, prospective and open-label interventional clinical trial of end stage renal failure patients on hemodialysis.Primary outcome will be absolute difference in coronary artery calcium (CAC) score at 18-month between control and intervention arms. Secondary outcomes will be to compare absolute difference in aortic valve calcification, percentage of patients with regression of coronary artery calcification of at least 10%, absolute difference in aortic and systemic arterial stiffness, mortality from any cause and major adverse cardiovascular events (MACE) over the same period.


Recruitment information / eligibility

Status Completed
Enrollment 178
Est. completion date February 2022
Est. primary completion date February 2022
Accepts healthy volunteers No
Gender All
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: 1. Age = 45 years and less than 80 years 2. At least 12 months on Hemodialysis 3. Coronary artery calcium score of = 30 in the baseline Multislice Computed Tomography 4. Able to give informed consent 5. Life expectancy of at least18 months Exclusion Criteria: 1. History of thrombosis in the last 6 months except vascular access thrombosis 2. Need for vitamin K antagonists therapy at baseline or in the 3 months prior to baseline 3. Presence of significant gut disease (inflammatory bowel disease, short-bowel syndrome) 4. Liver dysfunction 5. Alcohol or drug abuse 6. Presence of coronary stent or have undergone coronary artery bypass grafting 7. Women who are pregnant or breast feeding, 8. Those who are fearful of confined space and cannot lie still for Multislice Computed Tomography 9. Lack of safe contraceptive measures. 10. Those who had parathyroid surgery done. 11. Those with parathyroid hormone (PTH) > 150 pmol/l 12. Patient taking multivitamins containing vitamin K 13. Patient allergic to soy based products

Study Design


Intervention

Drug:
menaquinone-7
Oral supplement given post dialysis 3x/week

Locations

Country Name City State
Singapore National University Hospital Singapore

Sponsors (3)

Lead Sponsor Collaborator
National University Health System, Singapore National Medical Research Council (NMRC), Singapore, Nattopharma ASA

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Absolute difference in coronary artery calcium score at 18-month between control and intervention arms Comparison made using the t-test following log transformation. Adjustment for baseline CAC scores made via the analysis of covariance. 18 months
Secondary Absolute difference in AVC score at 18-months Comparison made using the t-test following log transformation. Adjustment for baseline AVC scores made via the analysis of covariance. 18 months
Secondary Percentage of patients with regression of CAC of = 10% over 18-month 18 months
Secondary Absolute difference in cfPWV and AI at 18-months 18 months
Secondary Mortality from any cause within the study period 18 months
Secondary MACE defined as non-fatal myocardial infarction, heart failure, acute coronary syndrome, need for coronary revascularization, non-fatal stroke, significant peripheral vascular disease 18 months
Secondary Difference in plasma levels of dp-ucMGP at 18 months 18 months
Secondary Vascular access events, including clotting requiring insertion of a new dialysis catheter, declotting or exchange of an existing catheter, and vascular intervention during the study period 18 months
See also
  Status Clinical Trial Phase
Completed NCT03960437 - The Effect of Etelcalcetide on CKD-MBD Phase 2
Recruiting NCT04983875 - Mammography and Breast Arterial Calcification: An Information-Sharing Trial N/A
Completed NCT03292029 - Pilot Medical Evaluation of the T50 Test N/A
Completed NCT02561299 - Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study N/A
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Active, not recruiting NCT02598635 - Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis Phase 4
Completed NCT00183001 - Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification Phase 3
Completed NCT04114695 - Aortic Calcification and Central Blood Pressure in Patients With Chronic Kidney Disease
Not yet recruiting NCT03169400 - Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) N/A
Completed NCT03314493 - Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients Phase 3
Completed NCT03839732 - Observer Variability in Scoring Abdominal Aortic Calcifications and Vertebral Morphometry
Completed NCT02542319 - Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease Phase 2
Completed NCT02610933 - Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients Phase 4
Completed NCT00481364 - Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients Phase 3
Completed NCT00694824 - Vascular Calcification's Risk Factors in Haemodialysis Patients
Recruiting NCT01364688 - Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease Phase 2
Completed NCT01675206 - Dose Defining Study for the Administration of Vitamin K2 Supplements in Hemodialysis Patients Phase 3
Completed NCT03937349 - Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients
Completed NCT02719665 - THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease N/A
Recruiting NCT04753593 - Use of Discarded Surgery Human Tissue Specimens for Basic Science Research